MLL Antibody (10F8D7): sc-101431
- MLL Antibody (10F8D7) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against a recombinant protein corresponding to amino acids 3751-3986 of MLL of human origin
- recommended for detection of MLL of human origin by WB, IP, IF, IHC(P) and ELISA
- m-IgG Fc BP-HRP is the preferred secondary detection reagent for MLL Antibody (10F8D7) for WB and IHC(P) applications. This reagent is now offered in a bundle with MLL Antibody (10F8D7) (see ordering information below).
MLL Antibody (10F8D7) is a mouse monoclonal IgG1 antibody that detects MLL in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). MLL, or myeloid/lymphoid leukemia protein, plays a crucial role in regulating embryonal and hematopoietic development, making MLL essential for proper cellular differentiation and proliferation. MLL is primarily located in the nucleus, where MLL functions as a transcriptional coactivator, influencing the expression of genes involved in cell growth and development. Nuclear localization allows MLL to interact with other transcription factors and chromatin-modifying complexes, thereby facilitating the transcription of target genes. Notably, the gene encoding human MLL is located on chromosome 11q23 and is frequently involved in translocations associated with acute myeloid leukemia, highlighting MLL′s significance in cancer biology. Anti-MLL antibody (10F8D7) is an invaluable tool for researchers studying gene regulation, cellular development, and the molecular mechanisms underlying leukemia.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MLL Antibody (10F8D7) References:
- Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. | Placke, T., et al. 2014. Blood. 124: 13-23. PMID: 24764564
- MLL leukemia and future treatment strategies. | Marschalek, R. 2015. Arch Pharm (Weinheim). 348: 221-8. PMID: 25740345
- Transcriptional activation by MLL fusion proteins in leukemogenesis. | Yokoyama, A. 2017. Exp Hematol. 46: 21-30. PMID: 27865805
- Targeting multiple nodes of MLL complexes to improve leukemia therapy. | Dafflon, C., et al. 2017. Oncotarget. 8: 90614-90615. PMID: 29207581
- Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia. | Matsuo, H., et al. 2018. Blood Adv. 2: 2879-2889. PMID: 30381403
- Novel therapeutic strategies for MLL-rearranged leukemias. | Wong, NM. and So, CWE. 2020. Biochim Biophys Acta Gene Regul Mech. 1863: 194584. PMID: 32534041
- Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. | Tirtakusuma, R., et al. 2022. Blood. 140: 1875-1890. PMID: 35839448
- The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML. | Rasouli, M., et al. 2023. Hemasphere. 7: e935. PMID: 37520776
- CRISPR-ChIP reveals selective regulation of H3K79me2 by Menin in MLL leukemia. | Gilan, O., et al. 2023. Nat Struct Mol Biol. 30: 1592-1606. PMID: 37679565
- Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia. | Lin, TL., et al. 2024. Blood Adv. 8: 261-275. PMID: 38048400
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MLL Antibody (10F8D7) | sc-101431 | 200 µg/ml | $316.00 | |||
MLL Antibody (10F8D7): m-IgG Fc BP-HRP Bundle | sc-539764 | 200 µg Ab; 10 µg BP | $354.00 |